BIOMAT Database Logo BIOMAT Database Logo

Rationale for very high-dose chemotherapy with peripheral blood stem cell support in advanced ovarian cancer. 1990

P B Panici, and G Scambia, and G Baiocchi, and G Laurelli, and S Greggi, and F Battaglia, and G Ragusa, and G Salerno, and A Gallo, and R Cento
Divisione di Ginecologia, Università Cattolica, Roma, Italy.

Although significant progress has been made in the management of advanced ovarian cancer, the majority of patients continue to die of this disease. Most advanced ovarian cancer patients present sub-optimal residual tumour after primary surgery and their prognosis is very poor since residual disease has been confirmed as the major factor predicting response to chemotherapy and survival. Therefore, it seems worth developing treatment modalities that can produce a longer remission period. In this short review, the authors summarize the clinical and experimental evidence supporting the usefulness of high-dose chemotherapy with autologous peripheral blood stem cell transplantation in advanced ovarian cancer.

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D001804 Blood Transfusion, Autologous Reinfusion of blood or blood products derived from the patient's own circulation. (Dorland, 27th ed) Autotransfusion,Autologous Blood Transfusion,Autologous Blood Transfusions,Blood Transfusions, Autologous,Transfusion, Autologous Blood,Transfusions, Autologous Blood,Autotransfusions
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D018380 Hematopoietic Stem Cell Transplantation Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. Stem Cell Transplantation, Hematopoietic,Transplantation, Hematopoietic Stem Cell

Related Publications

P B Panici, and G Scambia, and G Baiocchi, and G Laurelli, and S Greggi, and F Battaglia, and G Ragusa, and G Salerno, and A Gallo, and R Cento
High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer.
April 2001, Journal of cancer research and clinical oncology,
P B Panici, and G Scambia, and G Baiocchi, and G Laurelli, and S Greggi, and F Battaglia, and G Ragusa, and G Salerno, and A Gallo, and R Cento
High-dose chemotherapy with autologous stem cell support in advanced ovarian cancer.
April 1996, Annals of medicine,
P B Panici, and G Scambia, and G Baiocchi, and G Laurelli, and S Greggi, and F Battaglia, and G Ragusa, and G Salerno, and A Gallo, and R Cento
High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer.
March 2002, International journal of urology : official journal of the Japanese Urological Association,
P B Panici, and G Scambia, and G Baiocchi, and G Laurelli, and S Greggi, and F Battaglia, and G Ragusa, and G Salerno, and A Gallo, and R Cento
High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer.
July 2000, International journal of urology : official journal of the Japanese Urological Association,
P B Panici, and G Scambia, and G Baiocchi, and G Laurelli, and S Greggi, and F Battaglia, and G Ragusa, and G Salerno, and A Gallo, and R Cento
[High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer].
August 2002, Hinyokika kiyo. Acta urologica Japonica,
P B Panici, and G Scambia, and G Baiocchi, and G Laurelli, and S Greggi, and F Battaglia, and G Ragusa, and G Salerno, and A Gallo, and R Cento
Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer.
October 2006, Bone marrow transplantation,
P B Panici, and G Scambia, and G Baiocchi, and G Laurelli, and S Greggi, and F Battaglia, and G Ragusa, and G Salerno, and A Gallo, and R Cento
[Ovarian cancer treated with very-high-dose chemotherapy and peripheral hematopoietic stem cell transplantation].
February 1998, Zhonghua fu chan ke za zhi,
P B Panici, and G Scambia, and G Baiocchi, and G Laurelli, and S Greggi, and F Battaglia, and G Ragusa, and G Salerno, and A Gallo, and R Cento
High dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer.
January 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
P B Panici, and G Scambia, and G Baiocchi, and G Laurelli, and S Greggi, and F Battaglia, and G Ragusa, and G Salerno, and A Gallo, and R Cento
[High dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) For advanced testicular cancer].
May 1998, Hinyokika kiyo. Acta urologica Japonica,
P B Panici, and G Scambia, and G Baiocchi, and G Laurelli, and S Greggi, and F Battaglia, and G Ragusa, and G Salerno, and A Gallo, and R Cento
High-dose chemotherapy with autologous stem-cell support for epithelial ovarian cancer.
January 1999, Tecnologica. MAP supplement. Blue Cross and Blue Shield Association. Medical Advisory Panel,
Copied contents to your clipboard!